By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Savara Inc.

Savara Inc. (SVRA)

NASDAQ Currency in USD
$3.59
-$0.24
-6.27%
Last Update: 11 Sept 2025, 20:00
$620.48M
Market Cap
-117.70
P/E Ratio (TTM)
Forward Dividend Yield
$1.89 - $4.70
52 Week Range

SVRA Stock Price Chart

Explore Savara Inc. interactive price chart. Choose custom timeframes to analyze SVRA price movements and trends.

SVRA Company Profile

Discover essential business fundamentals and corporate details for Savara Inc. (SVRA) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

28 Apr 2017

Employees

59.00

CEO

Matthew Pauls

Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

SVRA Financial Timeline

Browse a chronological timeline of Savara Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 11 May 2026

Upcoming earnings on 11 Nov 2025

EPS estimate is -$0.12.

Earnings released on 13 Aug 2025

EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%.

Earnings released on 13 May 2025

EPS came in at -$0.12 matching the estimated -$0.12.

Earnings released on 27 Mar 2025

EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%, while revenue for the quarter reached $272.00K .

Earnings released on 12 Nov 2024

EPS came in at -$0.11 matching the estimated -$0.11.

Earnings released on 12 Aug 2024

EPS came in at -$0.12 falling short of the estimated -$0.11 by -9.09%.

Earnings released on 9 May 2024

EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%.

Earnings released on 7 Mar 2024

EPS came in at -$0.09 surpassing the estimated -$0.11 by +18.18%.

Earnings released on 9 Nov 2023

EPS came in at -$0.10 falling short of the estimated -$0.07 by -42.86%.

Earnings released on 10 Aug 2023

EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.

Earnings released on 15 May 2023

EPS came in at -$0.07 matching the estimated -$0.07.

Earnings released on 30 Mar 2023

EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.

Earnings released on 10 Nov 2022

EPS came in at -$0.07 matching the estimated -$0.07.

Earnings released on 11 Aug 2022

EPS came in at -$0.06 matching the estimated -$0.06.

Earnings released on 11 May 2022

EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%.

Earnings released on 30 Mar 2022

EPS came in at -$0.07 matching the estimated -$0.07.

Earnings released on 12 Nov 2021

EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.

Earnings released on 12 Aug 2021

EPS came in at -$0.07 surpassing the estimated -$0.12 by +41.67%.

Earnings released on 13 May 2021

EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%.

Earnings released on 10 Mar 2021

EPS came in at -$0.23 falling short of the estimated -$0.10 by -130.00%, while revenue for the quarter reached $1.00K .

Earnings released on 5 Nov 2020

EPS came in at -$0.18 surpassing the estimated -$0.20 by +10.00%, while revenue for the quarter reached $256.00K , beating expectations by +5.88%.

SVRA Stock Performance

Access detailed SVRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run